Xenical Pediatric AERs Need Continued Monitoring, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Pediatric adverse events associated with Roche's Xenical (orlistat) could be a concern for FDA when an attempt is made to switch the drug over the counter